Coherus BioSciences Inc.
1.45
-0.02 (-1.36%)
At close: Jan 14, 2025, 3:59 PM
1.49
2.76%
After-hours Jan 14, 2025, 04:40 PM EST
undefined%
Bid 1.4
Market Cap 167.06M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.09
PE Ratio (ttm) -16.11
Forward PE n/a
Analyst Buy
Ask 1.55
Volume 2,108,460
Avg. Volume (20D) 5,060,686
Open 1.47
Previous Close 1.47
Day's Range 1.45 - 1.60
52-Week Range 0.66 - 2.97
Beta undefined

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2014
Employees 235
Stock Exchange NASDAQ
Ticker Symbol CHRS

Analyst Forecast

According to 4 analyst ratings, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 382.76% from the latest price.

Buy 75.00%
Hold 25.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Coherus BioSciences Inc. is scheduled to release its earnings on Mar 12, 2025, during market hours.
Analysts project revenue of $43.88M, reflecting a -52.06% YoY shrinking and earnings per share of -0.18, making a -70.97% decrease YoY.
1 month ago · Source
+24.82%
Coherus Biosciences shares are trading higher afte... Unlock content with Pro Subscription
2 months ago · Source
+13.29%
Coherus BioSciences shares are trading higher after the company reported better-than-expected Q3 financial results.